Erratum: Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets (Medicine and Science in Sports and Exercise 95:30 (e4321) DOI: 10.1097/MD.0000000000004321);Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets

Medicine (United States)

Volumn 95, Issue 30, 2016, Pages

  Wang, Xiaosheng ^a   Guda, Chittibabu ^b,c,d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Cell Biology and Anatomy ^*  (China)

^c Bioinformatics and Systems Biology Core   (China)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

copy number variation; gene expression profiling; methylation; microRNA; somatic mutation; targeted therapy; triple negative breast cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPHRIN RECEPTOR B3; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 13; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN BCL 2; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; CSF1R GENE; DNA METHYLATION; EPHB3 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; GENE BCL 2; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE P53; GENETIC ANALYSIS; GENOMICS; HUMAN; LAD1 GENE; MAPK13 GENE; MOLECULARLY TARGETED THERAPY; MUCIN GENE; ONCOGENE; ONCOGENE SRC; PRIORITY JOURNAL; TRIB1 GENE; TRIPLE NEGATIVE BREAST CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; SRC-FAMILY KINASES; TRANSCRIPTIONAL ACTIVATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84982783994     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/01.md.0000503499.57465.64     Document Type: Erratum

References (51)

1. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008;22:1233-9. discussion 1239-1240, 1243.
2. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-27.
3. Sikov W, Berry D, Perou C, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dosedense AC on pathologic complete response rates in triple-negative breast cancer. San Antonio:Breast Cancer Symposium; 2013.
4. Bayraktar S, Gluck S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 2013;138:21-35.
5. Rugo H, Olopade O, DeMichele A, et al. I-SPY 2 Site PI'sVeliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. San Antonio:Breast Cancer Symposium; 2013.
6. Patel L, Parker B, Yang D, et al. Translational genomics in cancer research: converting profiles into personalized cancer medicine. Can Biol Med 2013;10:214-20.
7. Marcotte R, Sayad A, Brown KR, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 2016;164:293-309.
8. Cancer Genome Atlas NetworkNetwork TCGA: Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70
9. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
10. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
11. Cancer Genome Atlas Research NetworkComprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
12. Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014;16:406.
13. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395-9.
14. Craig DW, O'Shaughnessy JA, Kiefer JA, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 2013; 12:104-16.
15. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007;17:1665-74.
16. Benjami Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289-300.
17. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
18. Mi H, Muruganujan A, Casagrande JT, et al. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 2013; 8:1551-66.
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
20. Baker L, Quinlan PR, Patten N, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 2010;102:719-26.
21. Lamb R, Ablett MP, Spence K, et al. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One 2013;8:e67811.
22. Alistar A, Chou JW, Nagalla S, et al. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome medicine 2014;6:80.
23. Turner N, Moretti E, Siclari O, et al. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev 2013;39:541-50.
24. Workman HC, Miller JK, Ingalla EQ, et al. The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Res 2009;11:R70.
25. Mukhopadhyay P, Lakshmanan I, Ponnusamy MP, et al. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. PLoS One 2013;8: e54455.
26. Lakshmanan I, PonnusamyMP, Das S, et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012;31:805-17.
27. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
28. Wang X, Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics 2013;6:30.
29. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
30. Kluger HM, Dolled-Filhart M, Rodov S, et al. Macrophage colonystimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004;10(1 pt 1):173-7.
31. Mashkani B, Griffith R, Ashman LK. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem 2010;18:1789-97.
32. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012;2012: 217185.
33. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010;16: 3526-32.
34. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012;33: 122-8.
35. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15:419-33.
36. Fletcher MN, Castro MA, Wang X, et al. Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun 2013;4:2464.
37. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29:2013-23.
38. Giltnane JM, Balko JM. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med 2014;17:275-83.
39. Mashima T, Soma-Nagae T, Migita T, et al. TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Res 2014;74: 4888-97.
40. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
41. Heiser LM, Sadanandam A, Kuo WL, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2012;109:2724-9.
42. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-40.
43. Ye T, Wei X, Yin T, et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat 2014;143:435-46.
44. Kuo WL, Das D, Ziyad S, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med 2009;7:77.
45. vonMinckwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 2012;23(suppl 6):vi35-9.
46. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27:6398-406.
47. Xie M, Doetsch PW, Deng X. Bcl2 inhibition of mitochondrial DNA repair. BMC Cancer 2015;15:586.
48. XieM, Park D, You S, et al. Bcl2 inhibits recruitment ofMre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation. Nucleic Acids Res 2015;43:960-72.
49. Shiang C. Novel therapeutic targets identified by high-throughput technologies for triple-negative breast cancer. Houston, Texas:Texas Medical Center Library: The University of Texas Health Science Center at Houston; 2013.
50. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011;16(suppl 1):1-1.
51. Dent RA, Lindeman GJ, ClemonsM, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88.